Atara Biotherapeutics (ATRA) Current Leases (2019 - 2026)

Atara Biotherapeutics has reported Current Leases for 8 years, with the latest figure at $1.0 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases fell 5.23% year-over-year to $1.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.0 million (down 5.23% YoY), and the FY2025 full-year result was $1.0 million, down 0.96% from the prior year.
• Current Leases for Q1 2026 stood at $1.0 million, down from $1.0 million in the prior quarter.
• The five-year high for Current Leases was $13.0 million in Q2 2024, with the low at $832000.0 in Q1 2023.
• Historically, Current Leases has averaged $3.7 million across 5 years, with a median of $1.0 million in 2025.
• Annual changes were most pronounced in 2022 — Current Leases jumped 7388.89% — and 2024, when it tumbled 90.78%.
• Atara Biotherapeutics' Current Leases stood at $12.8 million in 2022, then declined by 12.04% to $11.3 million in 2023, then plunged by 90.78% to $1.0 million in 2024, then dropped by 0.96% to $1.0 million in 2025, then fell by 1.36% to $1.0 million in 2026.
• The last three Current Leases figures came in at $1.0 million (Q1 2026), $1.0 million (Q4 2025), and $2.2 million (Q2 2025), per Business Quant data.